1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Colon Carcinoma - Pipeline Review, H2 2014

Colon Carcinoma - Pipeline Review, H2 2014

  • August 2014
  • -
  • Global Markets Direct
  • -
  • 53 pages

Colon Carcinoma - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Colon Carcinoma - Pipeline Review, H2 2014’, provides an overview of the Colon Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colon Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Colon Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Colon Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Colon Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Colon Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Colon Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Colon Carcinoma - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Colon Carcinoma Overview 7
Therapeutics Development 8
Pipeline Products for Colon Carcinoma - Overview 8
Pipeline Products for Colon Carcinoma - Comparative Analysis 9
Colon Carcinoma - Therapeutics under Development by Companies 10
Colon Carcinoma - Therapeutics under Investigation by Universities/Institutes 11
Colon Carcinoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Colon Carcinoma - Products under Development by Companies 15
Colon Carcinoma - Products under Investigation by Universities/Institutes 16
Colon Carcinoma - Companies Involved in Therapeutics Development 17
Aposense Ltd. 17
Teva Pharmaceutical Industries Limited 18
Patrys Limited 19
Philogen S.p.A. 20
AIMM Therapeutics B.V. 21
Colon Carcinoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
CEP-37250 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
PAT-LM1 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ATT-11T - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
CIGB-247 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Antibody for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecules to Inhibit Tubulin for Oncology - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Monoclonal Antibody for Colon Carcinoma - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
methoxynaphthylfenoterol - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Vaccine for Lymphoma and Colon Carcinoma - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Recombinant Protein to Activate IL-2 Receptor for Oncology - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Adhesio-mAb - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Anti-MFG-E8 Mab - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
F8IL-4 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Peptide for Colon Carcinoma - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Antibody to Inhibit Rspo2 and Rspo3 for Oncology - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Colon Carcinoma - Recent Pipeline Updates 50
Colon Carcinoma - Dormant Projects 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables

Number of Products under Development for Colon Carcinoma, H2 2014 8
Number of Products under Development for Colon Carcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Colon Carcinoma - Pipeline by Aposense Ltd., H2 2014 17
Colon Carcinoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 18
Colon Carcinoma - Pipeline by Patrys Limited, H2 2014 19
Colon Carcinoma - Pipeline by Philogen S.p.A., H2 2014 20
Colon Carcinoma - Pipeline by AIMM Therapeutics B.V., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Colon Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 50
Colon Carcinoma - Dormant Projects, H2 2014 51

List of Figures

Number of Products under Development for Colon Carcinoma, H2 2014 8
Number of Products under Development for Colon Carcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Target, H2 2014 23
Number of Products by Stage and Top 10 Target, H2 2014 24
Number of Products by Top 10 Mechanism of Action, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 26
Number of Products by Top 10 Route of Administration, H2 2014 27
Number of Products by Stage and Top 10 Route of Administration, H2 2014 28
Number of Products by Top 10 Molecule Type, H2 2014 29
Number of Products by Stage and Top 10 Molecule Type, H2 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Cancer
Therapy
R&D
Research And Development

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.